Futura Medical to Host R&D Day in February 2019

17 December 2018

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces plans to host an R&D Day in London for analysts and institutional investors on Monday 11 February 2019.

The event will feature a presentation from a Key Opinion Leader in erectile dysfunction (“ED”) and will provide an opportunity to hear about the Company, its R&D strategy with a focus on its DermaSys® drug delivery technology and lead product MED2005, a topical glyceryl trinitrate (“GTN”) gel for the treatment of ED.

James Barder, Chief Executive Officer of Futura Medical, said: “We are looking forward to hosting the event which will build on our initial Advisory Panel meeting hosted by Futura at the 19th Annual Fall Scientific Meeting of Sexual Medicines Society of North America in November 2018, and was extremely well received and productive. The Advisory Panel were unanimous in their view that there has been little recent credible innovation in the treatment of ED. They were therefore excited by the meaningful PK and Phase 2 findings presented on our lead programme MED2005, demonstrating the potential of MED2005 as both a topical and fast-acting erectile dysfunction treatment, key differentiators to other ED products on the market. There was also a unanimous desire by the panel to remain involved with the development programme for MED2005 and the panel look forward to reviewing the results from our ongoing Phase 3 trial when published in Q4 2019.”

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...